Quantifying Drug Combination Synergy along Potency and Efficacy Axes

Area of Science:

• Pharmacology
• Computational Biology
• Oncology

Background:

• Drug combinations aim to reduce toxicity (synergistic potency) and improve outcomes (synergistic efficacy).
• Current synergy frameworks lack the precision to differentiate these goals, limiting the use of extensive chemical libraries.
• A need exists for a refined approach to drug combination analysis.

Purpose of the Study:

• To introduce multi-dimensional synergy of combinations (MuSyC), a novel formalism to decouple synergistic potency and efficacy.
• To demonstrate MuSyC's application in identifying optimal drug combinations for specific cancer types.

Main Methods:

• Developed MuSyC based on a generalized, multi-dimensional Hill equation.
• Applied MuSyC to analyze drug combinations in mutant-EGFR lung cancer and mutant-BRAF melanoma models.
• Investigated the impact of molecular correlates on drug response.

Main Results:

• MuSyC successfully distinguishes between synergistic potency and efficacy in drug combinations.
• In lung cancer, MuSyC identified combinations for synergistic potency (kinase inhibitors) and synergistic efficacy (epigenetic or microtubule targets).
• MuSyC precisely evaluated the effect of drug resistance mechanisms in melanoma.

Conclusions:

• MuSyC offers a precise framework for analyzing drug combinations, separating dose reduction from efficacy enhancement.
• This formalism can guide the translation of drug-combination screening results for improved therapeutic strategies.
• MuSyC has the potential to revolutionize drug combination discovery and development.